UY33102A - Antagonistas de pcsk9 - Google Patents
Antagonistas de pcsk9Info
- Publication number
- UY33102A UY33102A UY33102A UY33102A UY33102A UY 33102 A UY33102 A UY 33102A UY 33102 A UY33102 A UY 33102A UY 33102 A UY33102 A UY 33102A UY 33102 A UY33102 A UY 33102A
- Authority
- UY
- Uruguay
- Prior art keywords
- pcsk9 antagonists
- pcsk9
- antagonists
- Prior art date
Links
- 101001098868 Homo sapiens Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 title 1
- 102100038955 Proprotein convertase subtilisin/kexin type 9 Human genes 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28594209P | 2009-12-11 | 2009-12-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY33102A true UY33102A (es) | 2011-07-29 |
Family
ID=43466865
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY33102A UY33102A (es) | 2009-12-11 | 2010-12-13 | Antagonistas de pcsk9 |
Country Status (31)
Country | Link |
---|---|
US (1) | US8710192B2 (es) |
EP (1) | EP2510013B1 (es) |
JP (2) | JP5981347B2 (es) |
KR (1) | KR101915496B1 (es) |
CN (1) | CN102652139B (es) |
AR (1) | AR079336A1 (es) |
AU (1) | AU2010327924B2 (es) |
BR (1) | BR112012013782A8 (es) |
CA (1) | CA2781050C (es) |
CL (1) | CL2012001529A1 (es) |
CO (1) | CO6571886A2 (es) |
CR (1) | CR20120371A (es) |
CU (1) | CU24058B1 (es) |
EA (1) | EA032084B1 (es) |
EC (1) | ECSP12012034A (es) |
ES (1) | ES2726040T3 (es) |
GT (1) | GT201200189A (es) |
HN (1) | HN2012001223A (es) |
IL (1) | IL220091A0 (es) |
IN (1) | IN2012DN05237A (es) |
MA (1) | MA33903B1 (es) |
MX (1) | MX2012006648A (es) |
NZ (2) | NZ601084A (es) |
PE (1) | PE20121361A1 (es) |
PL (1) | PL2510013T3 (es) |
PT (1) | PT2510013T (es) |
TN (1) | TN2012000243A1 (es) |
TR (1) | TR201906696T4 (es) |
TW (1) | TWI523662B (es) |
UY (1) | UY33102A (es) |
WO (1) | WO2011072263A1 (es) |
Families Citing this family (136)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JOP20080381B1 (ar) | 2007-08-23 | 2023-03-28 | Amgen Inc | بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9) |
US20130064834A1 (en) | 2008-12-15 | 2013-03-14 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to pcsk9 |
JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
PL3395836T3 (pl) | 2011-01-28 | 2021-12-13 | Sanofi Biotechnology | Ludzkie przeciwciała przeciwko pcsk9 do zastosowania w sposobach leczenia konkretnych grup osobników |
US20140004142A1 (en) * | 2011-03-02 | 2014-01-02 | Pfizer Inc. | Pcsk9 vaccine |
AR088782A1 (es) * | 2011-04-29 | 2014-07-10 | Sanofi Sa | Sistemas de ensayo y metodos para identificar y caracterizar farmacos hipolipemiantes |
WO2012168491A1 (en) | 2011-06-10 | 2012-12-13 | Novartis Ag | Pharmaceutical formulations of pcsk9 antagonists |
WO2012170607A2 (en) * | 2011-06-10 | 2012-12-13 | Novartis Ag | Use of pcsk9 antagonists |
JP2013023499A (ja) * | 2011-07-14 | 2013-02-04 | Pfizer Inc | 抗pcsk9抗体を用いた処置 |
AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
AR087715A1 (es) | 2011-09-16 | 2014-04-09 | Lilly Co Eli | Anticuerpos anti pcsk9 y usos de los mismos |
EP2756004B1 (en) | 2011-09-16 | 2019-12-25 | Regeneron Pharmaceuticals, Inc. | INHIBITOR OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN-9 (PCSK9) FOR USE IN REDUCING LIPOPROTEIN(a) LEVELS |
TW201329104A (zh) | 2011-12-08 | 2013-07-16 | Amgen Inc | 人類lcat抗原結合蛋白質及其治療用途 |
WO2013091103A1 (en) | 2011-12-20 | 2013-06-27 | Adaerata, Limited Partnership | Single domain antibodies as inhibitors of pcsk9 |
US9255154B2 (en) | 2012-05-08 | 2016-02-09 | Alderbio Holdings, Llc | Anti-PCSK9 antibodies and use thereof |
CA2875096A1 (en) * | 2012-06-15 | 2013-12-19 | Genentech, Inc. | Anti-pcsk9 antibodies, formulations, dosing, and methods of use |
NZ704771A (en) | 2012-08-13 | 2018-02-23 | Regeneron Pharma | Anti-pcsk9 antibodies with ph-dependent binding characteristics |
EP2703009A1 (en) * | 2012-08-31 | 2014-03-05 | Sanofi | Combination treatments involving antibodies to human PCSK9 |
EP2706070A1 (en) * | 2012-09-06 | 2014-03-12 | Sanofi | Combination treatments involving antibodies to human PCSK9 |
EP4234694A3 (en) | 2012-11-21 | 2023-09-06 | Amgen Inc. | Drug delivery device |
US10287317B2 (en) * | 2013-02-15 | 2019-05-14 | Srx Cardio, Llc | Proprotein convertase subtilisin kexin type 9 (PCSK9) allosteric binding ligands to modulate serum low density lipoprotein (LDL) levels |
JP6768501B2 (ja) | 2013-03-15 | 2020-10-14 | アムゲン・インコーポレーテッド | 薬物カセット、自動注入機、および自動注入機システム |
JP6336564B2 (ja) | 2013-03-15 | 2018-06-06 | アムゲン・インコーポレーテッド | 薬物カセット、自動注入器、および自動注入器システム |
AU2014238267B2 (en) | 2013-03-22 | 2019-08-15 | Amgen Inc. | Injector and method of assembly |
US10111953B2 (en) | 2013-05-30 | 2018-10-30 | Regeneron Pharmaceuticals, Inc. | Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9) |
TWI682780B (zh) * | 2013-05-30 | 2020-01-21 | 美商再生元醫藥公司 | 醫藥組成物用於製造治療與pcsk9功能獲得性突變有關之體染色體顯性高膽固醇血症的藥物之用途 |
TW202021614A (zh) * | 2013-06-07 | 2020-06-16 | 法商賽諾菲生物技術公司 | 藉由投與pcsk9抑制劑抑制動脈粥狀硬化的方法 |
EP2862877A1 (en) | 2013-10-18 | 2015-04-22 | Sanofi | Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9 |
US20150004174A1 (en) * | 2013-06-28 | 2015-01-01 | Amgen Inc. | Methods for treating homozygous familial hypercholesterolemia |
JP7051293B2 (ja) | 2013-10-24 | 2022-04-11 | アムジエン・インコーポレーテツド | 温度感知制御を伴う薬剤送達システム |
KR102458637B1 (ko) | 2013-10-24 | 2022-10-24 | 암겐 인코포레이티드 | 주입기 및 조립 방법 |
EP3068803B1 (en) | 2013-11-12 | 2021-01-20 | Sanofi Biotechnology | Dosing regimens for use with pcsk9 inhibitors |
US8986691B1 (en) | 2014-07-15 | 2015-03-24 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
DE202014010499U1 (de) | 2013-12-17 | 2015-10-20 | Kymab Limited | Targeting von humaner PCSK9 zur Cholesterinbehandlung |
US8980273B1 (en) | 2014-07-15 | 2015-03-17 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
FR3014695A1 (es) * | 2013-12-17 | 2015-06-19 | Kymab Ltd | |
US9045548B1 (en) | 2014-07-15 | 2015-06-02 | Kymab Limited | Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment |
US9017678B1 (en) | 2014-07-15 | 2015-04-28 | Kymab Limited | Method of treating rheumatoid arthritis using antibody to IL6R |
US9051378B1 (en) | 2014-07-15 | 2015-06-09 | Kymab Limited | Targeting rare human PCSK9 variants for cholesterol treatment |
US9067998B1 (en) | 2014-07-15 | 2015-06-30 | Kymab Limited | Targeting PD-1 variants for treatment of cancer |
US9023359B1 (en) | 2014-07-15 | 2015-05-05 | Kymab Limited | Targeting rare human PCSK9 variants for cholesterol treatment |
US9914769B2 (en) | 2014-07-15 | 2018-03-13 | Kymab Limited | Precision medicine for cholesterol treatment |
US9034332B1 (en) | 2014-07-15 | 2015-05-19 | Kymab Limited | Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment |
US9045545B1 (en) | 2014-07-15 | 2015-06-02 | Kymab Limited | Precision medicine by targeting PD-L1 variants for treatment of cancer |
US8945560B1 (en) | 2014-07-15 | 2015-02-03 | Kymab Limited | Method of treating rheumatoid arthritis using antibody to IL6R |
US8992927B1 (en) | 2014-07-15 | 2015-03-31 | Kymab Limited | Targeting human NAV1.7 variants for treatment of pain |
US8883157B1 (en) | 2013-12-17 | 2014-11-11 | Kymab Limited | Targeting rare human PCSK9 variants for cholesterol treatment |
US8986694B1 (en) | 2014-07-15 | 2015-03-24 | Kymab Limited | Targeting human nav1.7 variants for treatment of pain |
US10994112B2 (en) | 2014-02-05 | 2021-05-04 | Amgen Inc. | Drug delivery system with electromagnetic field generator |
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
CA3193070A1 (en) | 2014-05-07 | 2015-11-12 | Amgen Inc. | Autoinjector with shock reducing elements |
SG11201609963PA (en) | 2014-06-03 | 2016-12-29 | Amgen Inc | Devices and methods for assisting a user of a drug delivery device |
US9139648B1 (en) | 2014-07-15 | 2015-09-22 | Kymab Limited | Precision medicine by targeting human NAV1.9 variants for treatment of pain |
EP3332790A1 (en) | 2014-07-15 | 2018-06-13 | Kymab Limited | Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations |
DE202015009006U1 (de) | 2014-07-15 | 2016-08-19 | Kymab Limited | Targeting von humaner PCSK9 zur Cholesterinbehandlung |
US9150660B1 (en) | 2014-07-15 | 2015-10-06 | Kymab Limited | Precision Medicine by targeting human NAV1.8 variants for treatment of pain |
WO2016008899A1 (en) | 2014-07-15 | 2016-01-21 | Kymab Limited | Targeting human pcsk9 for cholesterol treatment |
MX2017000627A (es) | 2014-07-16 | 2017-04-27 | Sanofi Biotechnology | Metodos para tratar pacientes con hipercolesterolemia familiar heterocigota (hfhe). |
WO2016023916A1 (en) | 2014-08-12 | 2016-02-18 | Kymab Limited | Treatment of disease using ligand binding to targets of interest |
EP3197492A1 (en) * | 2014-09-23 | 2017-08-02 | Pfizer Inc | Treatment with anti-pcsk9 antibodies |
US10695506B2 (en) | 2014-10-14 | 2020-06-30 | Amgen Inc. | Drug injection device with visual and audio indicators |
WO2016071701A1 (en) | 2014-11-07 | 2016-05-12 | Kymab Limited | Treatment of disease using ligand binding to targets of interest |
US10799630B2 (en) | 2014-12-19 | 2020-10-13 | Amgen Inc. | Drug delivery device with proximity sensor |
JP2017538512A (ja) | 2014-12-19 | 2017-12-28 | アムジエン・インコーポレーテツド | ライブボタンまたはユーザインタフェースフィールドを含む薬物送達装置 |
MX2017010466A (es) | 2015-02-17 | 2018-06-06 | Amgen Inc | Dispositivo de administracion de farmacos con sujecion asistida de vacio y/o respuestas. |
EP3981450A1 (en) | 2015-02-27 | 2022-04-13 | Amgen, Inc | Drug delivery device having a needle guard mechanism with a tunable threshold of resistance to needle guard movement |
MX2017011879A (es) * | 2015-03-20 | 2018-04-10 | Univ Aarhus | Inhibidores de pcsk9 para el tratamiento de trastornos del metabolismo de lipoproteínas". |
CN106084058B (zh) * | 2015-07-15 | 2019-08-27 | 北京天广实生物技术股份有限公司 | 抗人pcsk9单克隆抗体 |
CA2995645A1 (en) | 2015-08-18 | 2017-02-23 | Regeneron Pharmaceuticals, Inc. | Anti-pcsk9 inhibitory antibodies for treating patients with hyperlipidemia undergoing lipoprotein apheresis |
WO2017039786A1 (en) | 2015-09-02 | 2017-03-09 | Amgen Inc. | Syringe assembly adapter for a syringe |
JP7082568B2 (ja) | 2015-12-09 | 2022-06-08 | アムジエン・インコーポレーテツド | 信号伝達キャップ付き自動注射器 |
JP7032662B2 (ja) | 2015-12-31 | 2022-03-09 | ジエンス ヘンルイ メデイシンカンパニー リミテッド | Pcsk9抗体、その抗原結合フラグメント及び医薬用途 |
CN107531795B (zh) | 2016-01-05 | 2021-01-19 | 江苏恒瑞医药股份有限公司 | Pcsk9抗体、其抗原结合片段及其医药用途 |
WO2017120178A1 (en) | 2016-01-06 | 2017-07-13 | Amgen Inc. | Auto-injector with signaling electronics |
ES2814287T3 (es) | 2016-03-15 | 2021-03-26 | Amgen Inc | Reducir la probabilidad de rotura de cristal en dispositivos de administración de fármaco |
CN105801701B (zh) * | 2016-03-31 | 2019-03-29 | 河北仁博科技有限公司 | 一种pcsk9抗体的重链和轻链可变区及其应用 |
WO2017189089A1 (en) | 2016-04-29 | 2017-11-02 | Amgen Inc. | Drug delivery device with messaging label |
WO2017192287A1 (en) | 2016-05-02 | 2017-11-09 | Amgen Inc. | Syringe adapter and guide for filling an on-body injector |
ES2959783T3 (es) | 2016-05-13 | 2024-02-28 | Amgen Inc | Conjunto de cubierta protectora de vial |
EP3458988B1 (en) | 2016-05-16 | 2023-10-18 | Amgen Inc. | Data encryption in medical devices with limited computational capability |
EP3465124A1 (en) | 2016-06-03 | 2019-04-10 | Amgen Inc. | Impact testing apparatuses and methods for drug delivery devices |
WO2018004842A1 (en) | 2016-07-01 | 2018-01-04 | Amgen Inc. | Drug delivery device having minimized risk of component fracture upon impact events |
US20190328965A1 (en) | 2016-08-17 | 2019-10-31 | Amgen Inc. | Drug delivery device with placement detection |
WO2018081234A1 (en) | 2016-10-25 | 2018-05-03 | Amgen Inc. | On-body injector |
WO2018083248A1 (en) | 2016-11-03 | 2018-05-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
JOP20190112A1 (ar) | 2016-11-14 | 2019-05-14 | Amgen Inc | علاجات مدمجة لتصلب الشرايين، شاملة مرض قلبي وعائي تصلبي |
CA3049780A1 (en) | 2017-01-17 | 2018-07-26 | Amgen Inc. | Injection devices and related methods of use and assembly |
JP7064501B2 (ja) | 2017-02-17 | 2022-05-10 | アムジエン・インコーポレーテツド | 無菌流体流路を備える薬物送達デバイスおよび関連する組立方法 |
JP7280189B2 (ja) | 2017-02-17 | 2023-05-23 | アムジエン・インコーポレーテツド | 薬物送達装置用の挿入機構 |
EP3592403A1 (en) | 2017-03-06 | 2020-01-15 | Amgen Inc. | Drug delivery device with activation prevention feature |
CA3052482A1 (en) | 2017-03-07 | 2018-09-13 | Amgen Inc. | Needle insertion by overpressure |
IL268386B2 (en) | 2017-03-09 | 2023-11-01 | Amgen Inc | Insertion mechanism for a drug delivery device |
CN114588404A (zh) | 2017-03-28 | 2022-06-07 | 美国安进公司 | 柱塞杆和注射器组件***以及方法 |
MX2019012083A (es) | 2017-04-13 | 2019-11-21 | Cadila Healthcare Ltd | Nueva vacuna de peptidos contra la pcsk9. |
EP3634546A1 (en) | 2017-06-08 | 2020-04-15 | Amgen Inc. | Torque driven drug delivery device |
US11590294B2 (en) | 2017-06-08 | 2023-02-28 | Amgen Inc. | Syringe assembly for a drug delivery device and method of assembly |
JP7195276B2 (ja) | 2017-06-22 | 2022-12-23 | アムジエン・インコーポレーテツド | デバイス起動による衝突/衝撃の低減 |
WO2018237225A1 (en) | 2017-06-23 | 2018-12-27 | Amgen Inc. | ELECTRONIC DRUG DELIVERY DEVICE COMPRISING A CAP ACTIVATED BY A SWITCH ASSEMBLY |
JP7408398B2 (ja) | 2017-07-14 | 2024-01-05 | アムジエン・インコーポレーテツド | 二重ねじりばねシステムを有する針挿入後退システム |
WO2019018169A1 (en) | 2017-07-21 | 2019-01-24 | Amgen Inc. | PERMEABLE GAS SEALING ELEMENT FOR MEDICINE CONTAINER AND METHODS OF ASSEMBLY |
US11484648B2 (en) | 2017-07-25 | 2022-11-01 | Amgen Inc. | Drug delivery device with container access system and related method of assembly |
EP3658203B1 (en) | 2017-07-25 | 2022-08-31 | Amgen Inc. | Drug delivery device with gear module and related method of assembly |
WO2019032482A2 (en) | 2017-08-09 | 2019-02-14 | Amgen Inc. | HYDRAULIC-PNEUMATIC PRESSURE CHAMBER DELIVERY SYSTEM |
US11077246B2 (en) | 2017-08-18 | 2021-08-03 | Amgen Inc. | Wearable injector with sterile adhesive patch |
US11103636B2 (en) | 2017-08-22 | 2021-08-31 | Amgen Inc. | Needle insertion mechanism for drug delivery device |
WO2019070472A1 (en) | 2017-10-04 | 2019-04-11 | Amgen Inc. | FLOW ADAPTER FOR MEDICATION DELIVERY DEVICE |
EP4257164A3 (en) | 2017-10-06 | 2024-01-17 | Amgen Inc. | Drug delivery device with interlock assembly and related method of assembly |
EP3694578A1 (en) | 2017-10-09 | 2020-08-19 | Amgen Inc. | Drug delivery device with drive assembly and related method of assembly |
WO2019090086A1 (en) | 2017-11-03 | 2019-05-09 | Amgen Inc. | Systems and approaches for sterilizing a drug delivery device |
JP2021501616A (ja) | 2017-11-06 | 2021-01-21 | アムジエン・インコーポレーテツド | 配置及び流量検出を備える薬物送達デバイス |
MA50569A (fr) | 2017-11-06 | 2020-09-16 | Amgen Inc | Ensembles de remplissage-finition et procédés associés |
US11191904B2 (en) | 2017-11-10 | 2021-12-07 | Amgen Inc. | Plungers for drug delivery devices |
MA50903A (fr) | 2017-11-16 | 2021-05-12 | Amgen Inc | Auto-injecteur avec détection de décrochage et de point d'extrémité |
MA50904A (fr) | 2017-11-16 | 2020-09-23 | Amgen Inc | Mécanisme d'insertion d'aiguille pour dispositif d'administration de médicament |
US10835685B2 (en) | 2018-05-30 | 2020-11-17 | Amgen Inc. | Thermal spring release mechanism for a drug delivery device |
US11083840B2 (en) | 2018-06-01 | 2021-08-10 | Amgen Inc. | Modular fluid path assemblies for drug delivery devices |
EP3826699A1 (en) | 2018-07-24 | 2021-06-02 | Amgen Inc. | Delivery devices for administering drugs |
WO2020023336A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Hybrid drug delivery devices with grip portion |
US20210260279A1 (en) | 2018-07-24 | 2021-08-26 | Amgen Inc. | Hybrid drug delivery devices with optional grip portion and related method of preparation |
WO2020023444A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Delivery devices for administering drugs |
EP3829692A1 (en) | 2018-07-31 | 2021-06-09 | Amgen Inc. | Fluid path assembly for a drug delivery device |
MA53724A (fr) | 2018-09-24 | 2021-12-29 | Amgen Inc | Systèmes et procédés de dosage interventionnel |
CA3110371A1 (en) | 2018-09-28 | 2020-04-02 | Amgen Inc. | Muscle wire escapement activation assembly for a drug delivery device |
WO2020072698A1 (en) * | 2018-10-02 | 2020-04-09 | Exosome Therapeutics, Inc. | Compositions and methods for producing exosome loaded therapeutics for treating cardiovascular disease |
CA3110529A1 (en) | 2018-10-02 | 2020-04-09 | Amgen Inc. | Injection systems for drug delivery with internal force transmission |
WO2020072846A1 (en) | 2018-10-05 | 2020-04-09 | Amgen Inc. | Drug delivery device having dose indicator |
EA202191037A1 (ru) | 2018-10-15 | 2021-08-05 | Эмджен Инк. | Устройство доставки лекарственного средства, имеющее демпферный механизм |
AR116703A1 (es) | 2018-10-15 | 2021-06-02 | Amgen Inc | Proceso de ensamblaje de plataforma para un dispositivo de administración de fármacos |
MA54048A (fr) | 2018-11-01 | 2022-02-09 | Amgen Inc | Dispositifs d'administration de médicament avec rétraction partielle de l'organe d'administration de médicament |
MA54057A (fr) | 2018-11-01 | 2022-02-09 | Amgen Inc | Dispositifs d'administration de médicament à rétraction partielle d'élément d'administration de médicament |
TWI831847B (zh) | 2018-11-01 | 2024-02-11 | 美商安進公司 | 部分針頭縮回之藥物遞送裝置及其操作方法 |
MX2021008533A (es) | 2019-01-18 | 2021-08-19 | Astrazeneca Ab | Inhibidores de la pcsk9 y metodos de uso de los mismos. |
JP2022529319A (ja) | 2019-04-24 | 2022-06-21 | アムジエン・インコーポレーテツド | シリンジ滅菌確認アセンブリ及び方法 |
MX2021014015A (es) | 2019-05-17 | 2022-02-21 | Regeneron Pharma | Metodos basados en el genoma para reducir el riesgo cardiovascular. |
EP4017560A2 (en) | 2019-08-23 | 2022-06-29 | Amgen, Inc | Drug delivery device with configurable needle shield engagement components and related methods |
BR112023024278A2 (pt) | 2021-05-21 | 2024-01-30 | Amgen Inc | Método de otimizar uma receita de enchimento para um recipiente de fármacos |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5612114B2 (es) * | 1974-06-07 | 1981-03-18 | ||
AU548996B2 (en) | 1980-02-04 | 1986-01-09 | Merck & Co., Inc. | Tetrahydro-2h-pyran-2-one derivatives |
US4444784A (en) * | 1980-08-05 | 1984-04-24 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
NO177005C (no) * | 1988-01-20 | 1995-07-05 | Bayer Ag | Analogifremgangsmåte for fremstilling av substituerte pyridiner, samt mellomprodukter til bruk ved fremstillingen |
FI94339C (fi) * | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
US5177080A (en) * | 1990-12-14 | 1993-01-05 | Bayer Aktiengesellschaft | Substituted pyridyl-dihydroxy-heptenoic acid and its salts |
JP2648897B2 (ja) * | 1991-07-01 | 1997-09-03 | 塩野義製薬株式会社 | ピリミジン誘導体 |
US20110230392A1 (en) * | 1999-10-22 | 2011-09-22 | Millennium Pharmaceuticals, Inc. | Novel narc sc1, narc 10a, narc 1, narc 12, narc 13, narc17, narc 25, narc 3, narc 4, narc 7, narc 8, narc 11, narc 14a, narc 15, narc 16, narc 19, narc 20, narc 26, narc 27, narc 28, narc 30, narc 5, narc 6, narc 9, narc 10c, narc 8b, narc 9, narc2a, narc 16b, narc 1c, narc 1a, and narc 25 molecules and uses therefor |
AU2001241461A1 (en) | 2000-02-07 | 2001-08-14 | Millennium Pharmaceuticals, Inc. | Narc-1, novel subtilase-like homologs |
CA2553692C (en) | 2004-01-20 | 2014-10-07 | Kalobios, Inc. | Antibody specificity transfer using minimal essential binding determinants |
WO2006055778A2 (en) | 2004-11-16 | 2006-05-26 | Kalobios, Inc. | Immunoglobulin variable region cassette exchange |
US8211648B2 (en) | 2005-07-22 | 2012-07-03 | Kalobios Pharmaceuticals, Inc. | Secretion of antibodies without signal peptides from bacteria |
ES2366974T3 (es) * | 2006-05-05 | 2011-10-27 | Isis Pharmaceuticals, Inc. | Compuestos y procedimientos para modular la expresión de sglt2. |
ES2874149T3 (es) * | 2006-05-11 | 2021-11-04 | Alnylam Pharmaceuticals Inc | Composiciones y métodos para inhibir la expresión del gen PCSK9 |
US20100150937A1 (en) | 2006-11-07 | 2010-06-17 | Sparrow Carl P | Antagonists of pcsk9 |
US20100040611A1 (en) | 2006-11-07 | 2010-02-18 | Sparrow Carl P | Antagonists of pcsk9 |
JP5588175B2 (ja) * | 2006-11-07 | 2014-09-10 | メルク・シャープ・アンド・ドーム・コーポレーション | Pcsk9のアンタゴニスト |
JOP20080381B1 (ar) * | 2007-08-23 | 2023-03-28 | Amgen Inc | بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9) |
AR070315A1 (es) * | 2008-02-07 | 2010-03-31 | Merck & Co Inc | Anticuerpos 1b20 antagonistas de pcsk9 |
AR070316A1 (es) * | 2008-02-07 | 2010-03-31 | Merck & Co Inc | Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9) |
AU2009273768B2 (en) | 2008-07-25 | 2016-07-14 | Spp Industries Holdings Pty Ltd | A head rail for a blind |
TWI516501B (zh) * | 2008-09-12 | 2016-01-11 | 禮納特神經系統科學公司 | Pcsk9拮抗劑類 |
US8748115B2 (en) * | 2008-12-12 | 2014-06-10 | Merck Sharp & Dohme Corp. | PCSK9 immunoassay |
JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
-
2010
- 2010-12-09 AR ARP100104545A patent/AR079336A1/es unknown
- 2010-12-10 WO PCT/US2010/059959 patent/WO2011072263A1/en active Application Filing
- 2010-12-10 CN CN201080056182.4A patent/CN102652139B/zh active Active
- 2010-12-10 CA CA2781050A patent/CA2781050C/en not_active Expired - Fee Related
- 2010-12-10 PT PT10795172T patent/PT2510013T/pt unknown
- 2010-12-10 TR TR2019/06696T patent/TR201906696T4/tr unknown
- 2010-12-10 MX MX2012006648A patent/MX2012006648A/es active IP Right Grant
- 2010-12-10 PE PE2012000801A patent/PE20121361A1/es not_active Application Discontinuation
- 2010-12-10 TW TW099143361A patent/TWI523662B/zh not_active IP Right Cessation
- 2010-12-10 IN IN5237DEN2012 patent/IN2012DN05237A/en unknown
- 2010-12-10 US US12/965,743 patent/US8710192B2/en active Active
- 2010-12-10 EP EP10795172.5A patent/EP2510013B1/en active Active
- 2010-12-10 MA MA35037A patent/MA33903B1/fr unknown
- 2010-12-10 NZ NZ601084A patent/NZ601084A/en not_active IP Right Cessation
- 2010-12-10 JP JP2012543320A patent/JP5981347B2/ja not_active Expired - Fee Related
- 2010-12-10 BR BR112012013782A patent/BR112012013782A8/pt not_active IP Right Cessation
- 2010-12-10 PL PL10795172T patent/PL2510013T3/pl unknown
- 2010-12-10 KR KR1020127017876A patent/KR101915496B1/ko active IP Right Grant
- 2010-12-10 EA EA201200861A patent/EA032084B1/ru not_active IP Right Cessation
- 2010-12-10 NZ NZ625433A patent/NZ625433A/en not_active IP Right Cessation
- 2010-12-10 ES ES10795172T patent/ES2726040T3/es active Active
- 2010-12-10 AU AU2010327924A patent/AU2010327924B2/en not_active Ceased
- 2010-12-13 UY UY33102A patent/UY33102A/es not_active Application Discontinuation
-
2012
- 2012-05-21 TN TNP2012000243A patent/TN2012000243A1/en unknown
- 2012-05-31 IL IL220091A patent/IL220091A0/en unknown
- 2012-06-08 HN HN2012001223A patent/HN2012001223A/es unknown
- 2012-06-08 CL CL2012001529A patent/CL2012001529A1/es unknown
- 2012-06-08 GT GT201200189A patent/GT201200189A/es unknown
- 2012-06-11 CU CU2012000095A patent/CU24058B1/es active IP Right Grant
- 2012-07-11 CR CR20120371A patent/CR20120371A/es unknown
- 2012-07-11 CO CO12116665A patent/CO6571886A2/es active IP Right Grant
- 2012-07-11 EC ECSP12012034 patent/ECSP12012034A/es unknown
-
2016
- 2016-03-31 JP JP2016071758A patent/JP6297088B2/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP12012034A (es) | Antagonistas de pcsk9 | |
DK2414015T3 (da) | Laryngoskopsystem | |
DE112010004215A5 (de) | Hydrostataktor | |
DE112010002949A5 (de) | Kupplungstastpunkte | |
DK2411442T4 (da) | Umættet polyesterresin | |
BRPI1008827A2 (pt) | deisobutenizador | |
DK2430035T3 (da) | Uracylspipooxetannukleosider | |
FIC20230025I1 (fi) | neratinibi | |
BRPI1014968A2 (pt) | subalargador | |
DE112010002728A5 (de) | Turboinhalator | |
DE112009005323A5 (de) | Hebelarmprüfmaschine | |
DE112010004249A5 (de) | Spindelaktor | |
DE112009005462T8 (de) | Lenkungsssteuervorrichtung | |
BR112012004964A2 (pt) | girocóptero | |
BRPI1008070A2 (pt) | tricianoboratos | |
FI20095459A0 (fi) | Uusia määritysmenetelmiä | |
DK2483126T3 (da) | Skinnekøretøj | |
DE112010004865T8 (de) | Lamellennassreibkupplung | |
DK2506968T3 (da) | Faujasit-zeolit | |
DOP2011000348A (es) | Construcciones casb7439 | |
DE112010003255A5 (de) | Fördergutverteiler | |
BRPI1010159A2 (pt) | bistuti | |
BRPI1014668A2 (pt) | antagonistas ccr3 de arilsulfonamida | |
DE602010000025D1 (de) | Fahrzeugsitzgurtvorrichtung | |
ES1070429Y (es) | Traspaleta mejorada |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20181127 |